新单抗ZCH-7-2D3与白血病细胞的反应性及其临床意义

Reactivity of a novel monoclonal antibody ZCH-7-2D3 on leukemia cells and its clinical significance

目的:观察新抗人白细胞分化抗原ZCH-7-2D 3单克隆抗体(单抗)与白血病细胞的反应性及其在白血病免疫学诊断分型中的意义。方法:采用CD 45设门和多色流式细胞术,对经30余种标准单抗业已定型的100例白血病患者新鲜的骨髓细胞或外周血标本进行流式细胞术分析。结果:2D 3抗原在急性淋巴细胞性白血病(ALL)病例中的阳性率(10/31)明显低于急性髓细胞性白血病(AM L)(39/55,P<0.01);2D 3在3例B系/髓系混合型白血病病例中均有表达,而在6例慢性粒细胞性白血病(CM L)中不表达,在慢性淋巴细胞性白血病(CLL)中阳性率(3/5)与B系ALL病例中的阳性率(9/28)差异无显著意义(P=0.2389)。2D 3在ALL各免疫亚型中的表达差异无显著意义(P=0.5632);在AM L各亚型中除2例AM L-M 6患者不表达外,其余AM L亚型间无统计学意义(P>0.05)。结论:单抗2D 3主要与AM L细胞反应,但在识别白血病细胞分化阶段上未发现特殊性。

Objective： To analyze the reactive pattern and its clinical significance of ZCH-7-2D3 monoclonal antibody on leukemia cells. Methods： Bone marrow samples from 100 leukemia patients （male 59：female 41,34 cases of children and 66 adults,aged 11 months -- 77 year） were collected. A CD45 gating strategy and multi-parameter flow cytometry were used to analyze the leukemia cells. Results： The positive rate （10/31） of 2D3 antibody on acute lymphocytic leukemia （ALL） patients was significantly lower than that （39/55） of acute myelogeneous leukemia （AML） （P〈0. 01）. 2D3 was positive for all three cases of B/myeloid mixed lineage leukemia,but negative in 6 cases of chronic myelogeneous leukemia （CML）,significantly lower than that in AML（39/55,P〈0.01） patients. There was no difference between the positive rates of chronic lymphocytic leukemia （CLL, 3/5） and B lineage ALL （9/28, P = 0. 2389）. The antibody was not found to recognize the differentiation stages of either ALL and AML subtypes. Conclusion：2D3 monoclonal antibody primarily recognizes AML cases. Further studies on cloning of gene encoding the antigen protein and its biological functions are warranted.